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Abstract
 
We earlier found that a rat monoclonal antibody (mAb) RE2 can induce rapid death of murine
activated, but not resting, lymphocytes and lymphocyte cell lines, in a complement-independent
manner, a cell death differing from typical apoptosis or necrosis. We here found that this cell
death is independent of pathways involving Fas, caspase, and phosphoinositide-3 kinase. With
the advantage of producing human B cell line transfectants with stable expression of human/
mouse xeno-chimeric MHC class I genes, we found that RE2 epitope resides on the murine
class I 
 
 
 
2 domain. However, the 
 
 
 
3 domain plays a key role in transducing the death signal,
which mediates extensive aggregation of the MHC class I-integrin-actin filament system, giving
rise to membrane blebs and pores. In mouse models with T/NKT cell activation-associated ful-
minant hepatitis, administration of mAb RE2 almost completely inhibited the development of
liver cell injuries. Taken collectively, this form of cell death may be involved in homeostatic im-
mune regulation, and induction of this form of cell death using the mAbs may be potentially
therapeutic for subjects with immunological diseases mediated by activated lymphocytes.
Key words: adhesion molecule • cell death • cytoskeleton • immunotherapy • MHC class I
 
Introduction
 
Two types of cell death, apoptosis characterized by cellular
shrinkage, membrane blebbing, and nuclear disruption, and
necrosis characterized by cellular swelling, rupture of
plasma membrane, and swelling of mitochondria, both par-
ticipate in regulatory, protective, and pathogenic processes
in the immune system (1–3). In earlier studies, we inci-
dentally found that a rat mAb RE2, raised against MHC-
associated cell surface components of a T cell clone, has
the potential to specifically kill activated, but not resting,
murine lymphocytes and lymphocyte cell lines in the ab-
sence of complement, irrespective of mouse strains (4). This
pathway begins to occur rapidly and much faster than that
seen in a complement-dependent cytolysis, i.e. within 5
min after target cells were exposed to mAb RE2. Electron
microscopically, while dying cells formed gigantic pores on
the cell surface, there was neither indication of DNA frag-
mentation nor swelling of mitochondria during the cytoly-
sis; thus we considered it to be a novel form of cell death.
Although mAb RE2 killed only activated lymphocytes and
lymphocyte cell lines, it did immunoprecipitate 90, 60, and
44 kD molecules on the cell surface of virtually all organs,
irrespective of mouse strains. These findings suggested that
the target RE2 antigen resides on MHC class I molecules
and that some lymphocyte-unique class I–associated mole-
cules are also involved in this form of cell death.
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After this study, there were reports of human lympho-
cyte death induced by antibody-mediated ligation of HLA
class I molecules (5–7). Skov et al. (6) reported that ligation
of HLA class I molecules on human T cells induces cell
death through phosphoinositide-3 kinase (PI-3) kinase–
induced c-Jun NH2-terminal kinase activity, distinct from
that induced by the Fas/Fas ligand pathway. Genestier et al.
(8) demonstrated the anti-HLA class I–induced T cell
apoptosis that was inhibited by okadaic acid, an inhibitor of
phosphatases 1, 2A, and 2C. In the present studies, we in-
vestigated the RE2 epitope, and the mechanism of RE2-
mediated cell death was examined.
 
Materials and Methods
 
Mice and Cells.
 
C57BL/6 (B6) and MRL/
 
lpr
 
 mice were ob-
tained from Japan SLC Inc. Mouse strains deficient in 
 
 
 
2-micro-
globulin and TAP-1 were provided by Prof. H. Ishikawa, Keio
University School of Medicine (Tokyo, Japan). LFA-1–deficient
mice originally generated by R. Schmits et al. (9) were donated
by Dr. G. Matsumoto, Kanagawa Dental College (Kanagawa, Ja-
pan). IL-2–dependent T cell clone MS-S2 has been established
from a C3H mouse, as described previously (10).
 
mAbs and Reagents.
 
mAbs to murine CD3 (2C11), CD4
(GK1.5), CD8 (53–6.7), CD11a/LFA1 (M17/4), CD11b/Mac1
(M1/70), NK1.1 (PK136), and CD69 (H1.2F3) were purchased
from BD Biosciences. The rat mAb RE2 was raised by immuniz-
ing a rat with cell lysate of a mouse T cell clone, as described (4),
and purified using a protein G-Sepharose column (Pharmacia
LKB, Biotechnology AB). Latrunculin B was purchased from
Biomol Res. Lab., Z-VAD-fmk and Z-Asp-DCB from Peptide
Institute, Inc., Concanavalin A (Con A) from Seikagaku Co.
Other reagents used were purchased from Sigma-Aldrich.
 
Transfectants with Human/Mouse Chimeric MHC Class I Genes.
 
C1R cells (10
 
7
 
 cells), a human EBV-transformed B cell line defi-
cient in expressing HLA-A and -B genes (11), were transfected
with 20 
 
 
 
g/ml of human HLA B7, mouse H-2K
 
b
 
 and their hy-
brid genes (12), in the presence of 2 
 
 
 
g/ml of pSV-neo, using
electroporation method. Transfected cells were selected in geneti-
cin (0.25 mg/ml) in in vitro culture over a 4-wk period. Antibi-
otic-resistant clones were isolated and expanded, and expression of
the hybrid MHC class I molecules was confirmed, using flow cy-
tometric analysis with FACStar
 
PLUS™
 
 (Becton Dickinson).
 
Flow Cytometric Analysis and Cytotoxic Activity Assay.
 
Expres-
sion of RE2 molecules was analyzed by incubating target cells
with a rat mAb RE2, followed by FITC-conjugated mouse anti–
rat immunoglobulins on ice, and subjected to the analysis using
FACStar
 
PLUS™
 
. Assay for cytotoxic activity of mAb RE2 was
done by incubation of a mixture of target cells (10
 
7
 
 cells/ml) sus-
pended in RPMI 1640 medium supplemented with 2% de-com-
plemented fetal calf serum and the mAb (3 
 
 
 
g/ml) for 1 h at
37
 
 
 
C. Before incubation with mAb RE2, splenic cells were in-
cubated with Con A (2 
 
 
 
g/ml) for 24 h at 37
 
 
 
C. Percentages of
cell lysis were determined by trypan blue dye exclusion or by
propidium iodide (PI) staining of cells using FACStar
 
PLUS™
 
, in
triplicate. As the results using PI staining were almost identical to
those obtained by trypan blue dye exclusion, data of the latter
test were shown in the present studies. Potential inhibitors for
the cytotoxicity of mAb RE2 to MS-S2 cells, Z-VAD-fmk (13),
Z-Asp-DCB (14), LY294002 (15), okadaic acid (8), cytochalasin
D (16), and latrunculin B (17), were added in cell cultures 1 h
before, and wortmannin (6) 2 h before addition of mAb RE2.
Amounts of reagents used were determined by preliminary tests
for each inhibitor, referring to the methods described previously
(6, 8, 13–17).
 
Fluorescence Microscopic Studies.
 
MS-S2 cells were incubated
with Cy5.5-conjugated mAb RE2 for 10 min on ice, followed by
Alexa568-conjugated rat anti-LFA-1 mAb or anti-CD4 mAb and
Oregon Green 488–conjugated phalloidin for staining actin fila-
ments for 10 min on ice. After washing in cold PBS containing
2% FCS, cells were examined under an epi-fluorescence micro-
scope BX-60 (Olympus). Color image of cells for each dye was
acquired sequentially using cognate filter-set and cooled CCD
camera (PXL 1400; Photometrics), and then assigned pseudo-
color. Overlaid image was obtained by superposing pseudo-
color-assigned images.
 
Con A–induced Hepatitis Model.
 
Hepatitis was induced by giv-
ing an intravenous injection of 0.18 mg/mouse Con A dissolved
in pyrogen-free saline into 9-wk-old C57BL/6 mice. A group of
mice was given an intraperitoneal injection of mAb RE2 (0.8
mg/mouse) immediately after the Con A injection. As a control,
a comparable amount of polyclonal rat IgG (Sigma-Aldrich) was
injected. 24 h after the Con A injection, blood samples, liver tis-
sues, and liver mononuclear cells from these mice were collected.
Serum levels of glutamic oxaloacetic transaminase (GOT) and
Figure 1. (A) Effects of potential inhibitors on cytotoxic activity of mAb
RE2 to T cell clone MS-S2 cells. Inhibitors were added 1 or 2 h before the
cytotoxicity assay. Percentages of dead cells were determined by trypan
blue dye exclusion. (B) Cytotoxic sensitivity to mAb RE2 of Con A–acti-
vated splenic cells from various mouse strains. Splenic cells were first acti-
vated with 2  g/ml of Con A for 24 h at 37 C, and then incubated with
given concentrations of mAb RE2 for 1 h in the absence of complement.T
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glutamic pyruvic transaminase (GPT) were determined, using a
standard clinical automatic analyser (Hitachi, Type 7350). Liver
mononuclear cells were isolated as descried (18), double or triple
stained with a combination of PE-conjugated anti-CD69 mAb,
FITC-conjugated anti-NK1.1, anti-CD4, or anti-CD8 mAbs,
and APC-conjugated anti-CD3 mAb, and were subjected to the
analysis using FACStar
 
PLUS™
 
. For histopathological examinations,
liver tissues were fixed in 10% formalin, embedded in paraffin,
and stained with hematoxylin and eosin.
 
Results and Discussion
 
To precisely characterize the mechanism of mAb RE2-
induced cell death, we first examined effects of several po-
tential inhibitors on in vitro cytotoxic activity of mAb RE2
to the killing-susceptible murine T cell line MS-S2, in the
absence of complement. The caspase inhibitors, Z-VAD-
fmk (13) and Z-Asp-DCB (14); PI-3 kinase inhibitors,
wortmannin (6) and LY294002 (15), and an inhibitor of
phosphatase 1, 2A, 2C, okadaic acid (8) did not inhibit the
cytotoxic activity (Fig. 1 A). As Con A–activated splenic
cells from Fas-deficient MRL-
 
lpr/lpr
 
 mice were also sus-
ceptible to the cytotoxic activity of mAb RE2 (Fig. 1 B), it
was evident that this cell death differs from that involving
the Fas/Fas ligand, caspase, phosphatase 1, 2A, 2C, and PI-3
kinase pathways.
To determine whether the cell death is mediated by
MHC class I molecules, we examined the sensitivities to
mAb RE2 of Con A–activated splenic cells from mutant
mice deficient in TAP-1 (transporter associated with anti-
gen processing-1) and those deficient in 
 
 
 
2 microglobulin.
Compared with the finding in normal healthy C57BL/6
mice, splenic cells from these two mutant strains were both
resistant to the cytotoxic activity (Fig. 1 B). Based on these
data, we then investigated the RE2 epitope on mouse
MHC class I molecules, taking advantage of producing
transfectants of a HLA-A, -B negative human C1R cell
line of B cell origin, expressing xeno-chimeric MHC class
I molecules composed of either murine H-2K
 
b
 
 or human
HLA-B7 at 
 
 
 
1, 
 
 
 
2, and 
 
 
 
3 domains (Fig. 2). In flow cyto-
metric analysis of in vitro binding activities of mAb RE2,
only transfectants expressing class I molecules carrying mu-
rine 
 
 
 
2 domains were recognized by mAb RE2, while
others with human 
 
 
 
2 were negative, indicating that the
epitope resides on murine class I 
 
 
 
2 domain. Of note was
the finding, however, that when we examined the cyto-
toxic sensitivity of these transfectants to mAb RE2, only
those expressing class I with a combination of murine 
 
 
 
2
and human 
 
 
 
3 domains were killed. Thus, it is suggested
that after 
 
 
 
2 domain-mediated cross-linking of class I, 
 
 
 
3
domain may play a critical role in transducing death signals
to target cells, in a species-specific manner, i.e., human 
 
 
 
3
domain-mediated signal transduction to human target cells
and murine 
 
 
 
3 domain to murine target cells. Our trans-
fectants expressing 
 
 
 
3 domain of human MHC class I were
designed to carry the human cytoplasmic domain of class I
molecules (12). However, because the class I–mediated
signal transduction does not require the cytoplasmic do-
main (19), we assumed that some lymphocyte-unique 
 
 
 
3
domain-associated molecules are involved in this form of
cell death.
In this context, as shown in Fig. 1 A, we found that both
cytochalasin D that depolymerizes cytoskeletal actin fila-
ments to actin monomer (16) and latrunculin B that re-
duces the monomeric actin pool available for polymeriza-
tion (17) completely inhibited the mAb RE2-mediated
target MS-S2 cell lysis, while colchicine that depolymerizes
Figure 2. Expression of RE2
epitope and cytotoxic sensitivity
to mAb RE2 of the human
HLA-A, B-negative EBV-trans-
formed B cell line C1R, trans-
fected with xeno-chimeric MHC
class I genes composed of either
murine H-2Kb or human HLA-
B7 at  1,  2, and  3 domains.
Expression of RE2 molecules
was analyzed by incubating on
ice target cells with mAb RE2,
followed by FITC-conjugated
mouse anti–rat immunoglobu-
lins, and cells were subjected to
the analysis using FACStarPLUS™.
Cytotoxic sensitivity of transfec-
tants to mAb RE2 was analyzed,
as described in Materials and
Methods (right column).T
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microtubule filaments had no effects (4). Therefore, we
considered that the cell death is related to disorganization
of the cytoskeletal actin filament system through signals of
yet to be determined mediator molecules connected to
class I 
 
 
 
3 domain. There were reports indicating that both
MHC class I molecules and integrins are connected to cy-
toskeletal actin filament networks (20) and that one of the
antibodies to CD47, known as an integrin-associated pro-
tein, can induce rapid cell death resembling that induced by
mAb RE2 (21). To determine if the cell death involves in-
tegrin molecules, we examined whether anti-integrin mAb
may block the cytotoxic activity of mAb RE2 to MS-S2
cells. As shown in Fig. 1 A, an anti-integrin LFA-1 mAb
blocked, though not completely, the RE2-induced killing
of these cells, in a dose-dependent manner. To confirm this
finding, we then examined the cytotoxic sensitivity to
mAb RE2 of Con A–activated splenic cells from mice defi-
cient in LFA-1 (9). The results showed that these cells were
resistant, though not completely, to the cytotoxicity of
mAb RE2 (Fig. 1 B), thus indicating that LFA-1 plays an
important role for this form of cell death, as a mediator, al-
though other integrins and/or factors may also be involved
in this process. This raised a question if the effect of inte-
grin is ligand-dependent. Ligand binding by integrins is
known to require divalent cations. However, as addition of
EDTA in cell culture did not protect this mechanism of
cell death (4), the role of LFA-1 was thought to be ligand-
independent. Thus, it is suggested that the cell death is me-
diated by ligand-independent binding of integrins to MHC
class I 
 
 
 
3 domain, which eventually causes polymerization
Figure 3. Coaggregation of MHC class I (RE2), LFA-1, and actin filament networks on dying cells with membrane blebs. MS-S2 cells were stained
with mAb RE2 (red; A, F, K, and P), mAb LFA-1 (green; B, G, and L) and phalloidin for actin filaments (blue; C, H, M, and R). Coaggregation of these
three molecules is represented by overlaid images in white (D, I, and N). Control CD4 molecules were not colocalized with RE2 (P-S). Differential in-
terference contrast (DIC) images (E, J, O, and T) are also shown.T
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of actin filament networks, a hypothesis consistent with the
finding of species specificity of class I 
 
 
 
3–mediated signal
transduction, as shown in Fig. 2.
Involvement of MHC class I, LFA-1, and actin filament
system in this form of cell death was supported by triple
fluorochrome staining of the dying cells. Target MS-S2
cells were incubated on ice with a mixture of fluoro-
chrome-labeled mAb RE2, mAb LFA-1, and phalloidin
for actin filaments. Under the epi-fluorescent microscopic
examination, many membrane blebs formed all over the
cell surface. At an early phase, sizes of blebs were relatively
small and homogenous (Fig. 3, A–E). With time, there ap-
peared gigantic blebs (Fig. 3, F–J) and cytoplasmic struc-
tures were disorganized and polarized (Fig. 3, K–O). On
the cell membrane, RE2 (MHC class I), LFA-1, and actin
filaments were colocalized in an aggregated form (Fig. 3,
D, I, and N), and gigantic blebs were likely to have
formed from sites of disrupted MHC class I-integrin-actin
filament networks (Fig. 3 I). As a control, MS-S2 cells
were triple stained with mAbs RE2, anti-CD4, and phal-
loidin. As shown in Fig. 3, P–S, CD4 molecules were not
colocalized. Non-activated splenic cells or MS-S2 cells
treated with cytochalasin D were negative for these find-
ings (unpublished data).
Taken collectively, the cell death seen in the present
study appears to be initiated by extensive coligation of
MHC class I molecules through cross-linking of 
 
 
 
2 do-
mains by mAb RE2. Such cross-linked class I molecules
probably lead to aggregation of integrins, through class I 
 
 
 
3
domains, eventually causing disorganization of the cyto-
skeletal actin filament system, giving rise to formation of
large membrane blebs on the cell surface. Because an in-
crease in the cell surface density of class I molecules occurs
on activated lymphocytes (20), and because integrin like
LFA-1 is preferentially expressed on lymphocytes, only ac-
tivated lymphocytes are thought to be susceptible to the
cytotoxic activity of mAb RE2. However, the mechanism
of this type of cell death may be more complex, because
our preliminary data showed that the treatment of lympho-
cytes with IFN-
 
 
 
 alone, which up-regulates MHC class I,
but not LFA-1, expression, did not render cells susceptible
to the cytotoxicity of mAb RE2. Further studies on this
point are ongoing in our lab. The majority of murine anti-
MHC class I antibodies do not have the potential to kill ac-
Figure 4. Therapeutic effects of mAb RE2 on Con A–induced hepatitis in mice. (A) Serum levels of GOT and GPT in C57BL/6 mice (n   6) 24 h
after an intravenous injection of Con A, with or without administration of mAb RE2. Closed and open bars represent serum levels of GOT and GPT,
respectively. (B) Histopathology of massive liver cell necrosis seen in a mouse 24 h after an intravenous injection of Con A. (C) Absence of Con A-induced
liver cell necrosis in a mouse treated with mAb RE2. (D) Reduction of CD69-positive activated CD4  and CD8  T cells and NK1.1  CD3  NKT cells
in the liver of mice given Con A and mAb RE2 (bottom), compared with findings in mice given Con A alone (top). NKT cells were examined by triple
staining of cells with mAbs to CD69, NK1.1, and CD3, and gated CD3  cells were analyzed for CD69 and NK1.1, using FACStarPLUS™.T
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tivated lymphocytes in the manner seen with mAb RE2.
This can be attributed to the unique specificity of mAb
RE2 that recognizes a monomorphic cross-reactive epitope
of the MHC class I 
 
 
 
2 domain on both class I K and D
molecules (our unpublished data).
Because of its rapid and specific cytotoxic activity to ac-
tivated lymphocytes, we then attempted to apply this mAb
for therapy of Con A–induced hepatitis, an experimental
fulminant hepatitis model in mice. Con A causes severe
liver cell necrosis in mice within 6 h after an intravenous
injection. Development of this disease is mediated by acti-
vated T cells (22, 23) and NKT cells (18) and both TNF
 
 
 
and IFN-
 
 
 
 are thought to be critical mediators (18, 24). As
shown in Fig. 4, a significant elevation of serum glutamic
oxaloacetic transaminase (GOT) and glutamic pyruvic trans-
aminase (GPT) levels and histologically evident massive
liver cell necrosis were observed in C57BL/6 mice 24 h af-
ter an intravenous injection of Con A. In contrast, mice
given one intraperitoneal administration of mAb RE2 soon
after the Con A treatment showed an almost complete in-
hibition of such liver cell injuries. Polyclonal rat IgG used
as a control was without influence. As mononuclear cells
obtained from liver tissues of Con A–treated mice ex-
pressed up-regulated MHC class I molecules (unpublished
data), we then examined influences of mAb RE2 on acti-
vated T cells and NKT cells in the liver of Con A–treated
mice. As shown in Fig. 4 D, CD69
 
 
 
-activated CD4
 
 
 
 and
CD8
 
 
 
 T cells and CD69
 
 
 
NK1.1
 
 
 
CD3
 
 
 
 NKT cells were
all to a great extent reduced in mAb RE2-treated mice,
compared with findings in mice treated with Con A alone.
As a control, mice were treated with mAb RE2 alone.
There were no changes in the number and the frequency
of CD4
 
 
 
 and CD8
 
 
 
 T cells and NKT cells obtained from
liver tissues between mAb RE2-treated and nontreated
mice (unpublished data).
Our present findings may be important in two respects.
First, mAbs that have potential to induce the present form
of cell death could be used as an effective means for treat-
ing subjects with a variety of disorders mediated by aber-
rant activated or transformed lymphocytes such as trans-
plant rejection, autoimmune diseases, allergic diseases, and
lymphoma/leukemias. Second, this form of cell death may
play a part in immune regulation. In addition to the well-
established role for antigen presentation, MHC class I may
be involved at least in part in activation-induced cell
death, through mechanisms by which activated lympho-
cytes are eliminated by CD8
 
 
 
 T cells potentially recogniz-
ing the monomorphic portion of class I epitope such as
RE2. Involvement in the immune surveillance mechanism
for transformed lymphocytes is also possible, as most lym-
phocyte cell lines are sensitive to the cytotoxicity of mAb
RE2 (4).
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